Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 9c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.38, $0.09 worse than the analyst estimate of $1.47. Revenue for the quarter came in at $36.3 million versus the consensus estimate of $3.41 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Culp, Inc. (CULP) Misses Q4 EPS by 12c
• Innovex closes $95M acquisition of TCO Group AS